Aumolertinib is a third-generation molecular targeted drug that acts as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic activity. It inhibits mutant forms of EGFR, including the T790M mutation. Aumolertinib has demonstrated significant benefits over standard first- and second-generation treatments included in the WHO Essential Medicines List for NSCLC. It is currently under review for approval by the European Medicines Agency (EMA) .  Aumolertinib compound patent is expected to expire in 2035, and it has been granted in key countries of manufacture such as India, China and South Africa. Secondary patents may provide exclusivity in few LMICs until 2036-2039.

Patent & licence data in LMICs

Acronyms & abbreviations list